Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China multicenter registry and follow-up study of non-Hodgkin B-cell lymphoma
ChiCTR2000032263Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Distribution of non-Hodgkin B-cell lymphoma subtypes. Started Jul 2019; status: recruiting.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on ChiCTR2000032263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032263.